Problemas en el flujo de recursos ponen en riesgo la producción nacional de medicamentos

TL;DR

Rising labor costs, particularly due to minimum wage increases, are pressuring pharmaceutical companies.
Increased regulatory demands and significant investments in infrastructure and technology, often financed by loans, add to production costs.
The expansion of the Basic Health Plan (PBS) to include approximately 500 new medications strains the available financing from the Unit of Payment of Capacitation (UPC).
Healthcare providers (EPS) are experiencing significant payment delays to pharmaceutical manufacturers, with outstanding portfolios reaching up to $5 trillion Colombian pesos.
Patients are facing increased out-of-pocket expenses as they are sometimes unable to obtain medications through the healthcare system and must purchase them independently.
There is a lack of government incentives for local drug production, and bureaucratic delays at regulatory bodies like Invima hinder the introduction of new products and foreign investment.

Continuer la lecture de l'article original